Literature DB >> 4055114

Plasma exchange in progressive primary IgA nephropathy.

R Coppo, B Basolo, D Roccatello, O Giachino, D Lajolo, G Martina, C Rollino, A Amore, M Costa, G Piccoli.   

Abstract

Five patients with progressive primary IgA nephropathy (PIgAGN) were treated by plasma-exchange (PE) combined with immunosuppressive drugs. Circulating IgA-containing immune complexes (IgAIC), detected by a specific conglutinin solid phase assay, were monitored. Two patients with acute nephritic syndrome and rapidly progressing course, crescent formations and high levels of IgAIC had substantial lasting clinical improvement after several PE, with a fall in IgAIC levels. Another rapidly progressive case with marked sclerotic changes and a longer history of nephritic syndrome, but with normal levels of IgAIC, did not show any clinical improvement after PE. Two patients with a PIgAGN diagnosed several years before and presenting slowly evolutive course had no substantial clinical benefit from PE treatment. IgAIC levels, very high before PE temporarily decreased, but returned to the previous values after the end of the treatment. We conclude that PE combined with immunosuppressive treatment may be of clinical benefit for cases with acute nephritic syndrome of recent onset who still have high levels of IgAIC, even when important crescent formations are present.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055114

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  7 in total

1.  Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study.

Authors:  Jicheng Lv; Yihe Yang; Hong Zhang; Wenfang Chen; Xiaoxia Pan; Zhiling Guo; Caili Wang; Shen Li; Jianrong Zhang; Jianchun Zhang; Lijun Liu; Sufang Shi; Suxia Wang; Min Chen; Zhao Cui; Nan Chen; Xueqing Yu; Minghui Zhao; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Plasma exchange combined with immunosuppressive treatment in a child with rapidly progressive IgA nephropathy.

Authors:  Shuichiro Fujinaga; Yoshiyuki Ohtomo; Daisuke Umino; Hiroshi Mochizuki; Hitohiko Murakami; Toshiaki Shimizu; Yuichiro Yamashiro; Kazunari Kaneko
Journal:  Pediatr Nephrol       Date:  2007-02-07       Impact factor: 3.714

3.  Role of therapeutic apheresis in the treatment of pediatric kidney diseases.

Authors:  Shweta Shah; Catherine Joseph; Poyyapakkam Srivaths
Journal:  Pediatr Nephrol       Date:  2021-05-15       Impact factor: 3.714

4.  Diffuse Alveolar Hemorrhage in IgA Vasculitis with an Atypical Presentation.

Authors:  Yuhei Ito; Machiko Arita; Shogo Kumagai; Reoto Takei; Maki Noyama; Fumiaki Tokioka; Takumi Nagamoto; Chieko Kawakita; Kenichiro Asano; Chika Okita; Tadashi Ishida
Journal:  Intern Med       Date:  2017-10-16       Impact factor: 1.271

5.  B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis.

Authors:  Sigrid Lundberg; Emelie Westergren; Jessica Smolander; Annette Bruchfeld
Journal:  Clin Kidney J       Date:  2016-12-13

6.  Treating severe Henoch-Schönlein and IgA nephritis with plasmapheresis alone.

Authors:  Mohan Shenoy; Milos V Ognjanovic; Malcolm G Coulthard
Journal:  Pediatr Nephrol       Date:  2007-05-26       Impact factor: 3.651

7.  Chapter 10: Immunoglobulin A nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.